GEA
TGTX icon

Glen Eagle Advisors’s TG Therapeutics TGTX Stock Holding History

Glen Eagle Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$560 – 741
2018
Q3 		$560 Hold
100
– – ﹤0.01% 693
2018
Q2 		$1.31K Hold
100
– – ﹤0.01% 638
2018
Q1 		$1.42K Hold
100
– – ﹤0.01% 617
2017
Q4 		$820 Hold
100
– – ﹤0.01% 613
2017
Q3 		$1.19K Hold
100
– – ﹤0.01% 607
2017
Q2 		$1K Buy
+100
New +$1.12K ﹤0.01% 565

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glen Eagle Advisors's TGTX Position: Q4 2018 in Review

Glen Eagle Advisors sold out of TG Therapeutics (TGTX) in Q4 2018, closing a stake of 100 shares — an estimated $560 sold.

Glen Eagle Advisors first reported a position in TGTX in Q2 2017 and held it in 6 quarters. The position peaked at $1.42K in Q1 2018. 115 funds tracked by Wall St. Rank hold TGTX as of Q4 2018.

  • Glen Eagle Advisors reported no remaining TG Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Glen Eagle Advisors sold 100 TG Therapeutics shares in Q4 2018, an estimated $560.
  • Glen Eagle Advisors first reported a position in TG Therapeutics in Q2 2017 and held it in 6 quarters.
  • Glen Eagle Advisors's TG Therapeutics position peaked at $1.42K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2018.

Based on Glen Eagle Advisors's 13F filing for Q4 2018, filed 13 Aug 2024.